We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PET/CT Predicts Brain Tumors in Melanoma Patients

By HospiMedica International staff writers
Posted on 11 Jan 2024

Malignant melanoma, known for its aggressive nature and high potential for metastasis, holds the highest mortality rate among skin cancers. More...

Significantly, melanoma is also the third most frequent source of metastatic brain tumors, contributing to approximately 10% of all brain metastases. While F-18 FDG-PET/CT is recognized as an effective imaging technique for detecting melanoma metastases, its baseline prognostic significance in these cases is not well-documented. Now a new study has found that PET/CT scans might be capable of predicting the development of brain metastases in patients with melanoma

A team of researchers at the University Hospital Salzburg (Salzburg, Austria) conducted a retrospective study focusing on baseline F-18 FDG-PET/CT imaging parameters in melanoma patients. Their study linked these parameters to the onset of metastatic brain tumors. The research involved 159 consecutive melanoma patients who underwent F-18 FDG-PET/CT imaging at the hospital from 2008 to 2021 for initial staging and subsequent brain metastasis diagnosis during follow-ups. Baseline parameters from the PET/CT images were extracted and examined against the development of brain metastases using risk regression models. The median duration of follow-up was six years.

The study's results demonstrated that higher baseline peak standardized uptake values (pSULpeak), indicating maximum FDG radiotracer activity in the tumor, correlated with an increased and accelerated risk of brain tumors. For instance, a pSULpeak value of 19 translated to an 80% risk of brain metastasis within approximately 53 months, while a value of 26 indicated the same risk level within about 39 months. Therefore, higher baseline pSULpeak values increased the likelihood and hastened the onset of brain metastases in patients. These insights could enable healthcare providers to better identify patients who may need more frequent monitoring or could benefit from additional preventive treatments.

“Our results may suggest that in addition to clinical and pathological characteristics of tumors, F-18 FDG-PET/CT findings can be of value for prognostic risk stratification considering the occurrence of brain metastasis,” stated the researchers.

Related Links:
University Hospital Salzburg


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Glucose Meter
StatStrip®
Blood Gas Analyzer
i-Check200
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.